Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 09/26 05:35:20 pm
5099 GBp   -1.37%
09/26 ASTRAZENECA : Innovative pancreatic research expands treatment horiz..
09/23 ASTRAZENECA : Unique molecular atlas of pancreas produced
09/23 ASTRAZENECA : 23 September 2016 Innovative pancreatic research expan..
News SummaryMost relevantAll newsSector news 

AstraZeneca CEO Leaving As Profits Slide, Warns On Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 08:56am CEST

AstraZeneca PLC (AZN) Thursday said Chief Executive David Brennan is leaving after the troubled drug maker missed its first-quarter earnings and sales forecasts and cut its full-year profit targets yet again.

AstraZeneca, which reports in dollars, said net profit in the first three months of 2012 fell 44% to $1.64 billion from $2.91 billion a year earlier, missing analysts' expectations of $2.0 billion. Revenue was down 11% at $7.35 billion, compared with $8.29 billion a year earlier, worse than the $7.98 billion expected in a survey of 10 analysts.

Brennan, who used the update to announce his retirement, said, "The anticipated impact from the loss of exclusivity on several brands, together with challenging market conditions, has made for a difficult start to the year in revenue terms.

"Delivery on our restructuring plans and continued discipline on operating costs, together with the benefits from a lower tax rate, will only partially mitigate the revenue pressures. As a result we have lowered our core EPS [earnings per share] target for the full year to the range of $5.85 to $6.15."

The company previously foresaw core EPS coming in this year at $6.00 to $6.30, after $7.28 in 2011.

Brennan, an American, has been CEO since the start of 2006. Chief Financial Officer Simon Lowth will act as interim chief executive from June until a permanent successor is in place.

AstraZeneca faces crucial patent expiries between now and 2015 on products such as antipsychotic Seroquel and ulcer medicine Nexium, and the loss of patent protection in the U.S. in 2016 for its best-selling drug, heart drug Crestor. Coupled with a thinner late-stage pipeline and a mixed longer-term research and development track record, the U.K.'s No. 2 drug maker by sales has taken an aggressive approach to costs, shrinking operations and cutting thousands of jobs, while keeping cash flowing to shareholders.

In February, AstraZeneca announced it was cutting around 7,300 jobs as part of the company's ongoing cost-savings program. The first phase, launched in 2007, was aimed at improving long-term competitiveness and productivity. The second phase, announced in January 2010, envisioned the loss of up to 10,400 jobs by 2014.

Describing its outlook for 2012, the company said in a statement that "we now expect the decline in revenue for the full year will be in the range of the low to mid-teens in constant-currency terms."

AstraZeneca, which spent $5.6 billion last year buying back its own shares, Thursday said it spent $912 million in the first quarter on net stock repurchases.

AstraZeneca shares ended Wednesday at 2841 pence, down 6% on year-earlier levels.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
09/26 ASTRAZENECA : Innovative pancreatic research expands treatment horizons for peop..
09/23 ASTRAZENECA : Unique molecular atlas of pancreas produced
09/23 ASTRAZENECA : 23 September 2016 Innovative pancreatic research expands treatment..
09/22 ASTRAZENECA : provides update on cediranib EU marketing authorisation applicatio..
09/22 ASTRAZENECA : Diabetes drug combo shows positive results in late-stage study
09/22 Synairgen Interim Loss Widens As It Continues Development Programmes
09/21 ASTRAZENECA : Patients at the core of partnership
09/21 ASTRAZENECA : 21 September 2016 AstraZeneca provides update on cediranib EU mark..
09/21 ASTRAZENECA : Withdraws European Marketing Application For Cediranib
09/21 Indian pharma firms in global alliance to fight drug resistance
More news
Sector news : Pharmaceuticals - NEC
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Whose Drug Pipeline Impresses Most? A Rough Comparison Of GlaxoSmithKline And..
09/24 BIOTECH : What's Next For M&A?
09/23 Agenus' Immuno-Oncology Pipeline Has Promise
09/21 Allergan Sparks A Second Liver Disease Craze
09/21 ALLERGAN : Examining The Premiums Paid
Financials ($)
Sales 2016 23 292 M
EBIT 2016 5 459 M
Net income 2016 2 589 M
Debt 2016 11 860 M
Yield 2016 4,21%
P/E ratio 2016 33,50
P/E ratio 2017 30,39
EV / Sales 2016 4,15x
EV / Sales 2017 4,31x
Capitalization 84 837 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 69,1 $
Spread / Average Target 3,1%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results